Boardroom Alpha
Boardroom Alpha
JAZZ · Additional Proxy Materials (DEFA14A) · Filed July 14, 2026

Jazz Pharmaceuticals PLC — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
July 14, 2026
Ticker
JAZZ
Accession
0001628280-26-048166
Boardroom Alpha · Filing insights

Jazz Pharmaceuticals urges shareholders to vote FOR all director nominees and FOR five proposals at the 2026 AGM.

About Jazz Pharmaceuticals PLC
Market cap
$16.3B
1Y TSR
+114.5%
3Y TSR
+22.5%
Board grade
B-
Sector
Healthcare
CEO
Renee D Gala
Last annual meeting: Jul 23, 2026 · View full Jazz Pharmaceuticals PLC profile →
Document



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

(Amendment No.    )


Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐


Check the appropriate box:

☐    Preliminary Proxy Statement

☐    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐    Definitive Proxy Statement

☒    Definitive Additional Materials

☐    Soliciting Material Pursuant to Section 240.14a-12


JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

    No fee required.

☐    Fee paid previously with preliminary materials

☐    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.











The following e-mail was sent to employees of Jazz Pharmaceuticals plc on July 14, 2026.

Subject: From Neena Patil: An important reminder - Please vote your shares

imagea.jpg



Dear Jazzicians,

I am writing in connection with our 2026 Annual General Meeting of Shareholders (AGM) approaching on 23 July because many of you are shareholders in addition to being employees of Jazz Pharmaceuticals.

Please take a moment now to ensure that your shares are represented at this important meeting. As a Jazz Pharmaceuticals shareholder, your vote is very important.

We have a number of important proposals being voted on at the AGM. Jazz Pharmaceuticals’ board of directors and management team recommend that you vote your shares “FOR” each of the director nominees and “FOR” the other five proposals. Please refer to our proxy statement and the additional proxy materials that have been filed with the SEC for more details regarding the nominees and proposals.






If you were a shareholder on the record date 28 May 2026, you should have received instructions in the mail or electronically from your bank or broker about how to vote your shares and more information is provided below about E*Trade notifications.

Only shareholders of record at the close of business on the record date may vote at the AGM.

We encourage you to vote your shares as soon as possible.

For E*Trade employee stock plan services, please call +1.800.838.0908 (or 1.650.599.0125 if outside the US).

You may also reach out to Aislinn Doody or Julie Panigrahi for further assistance.

Thank you for your continued contributions to the growth and success of Jazz Pharmaceuticals and thank you in advance for voting promptly.

E*Trade Notifications:
If you hold shares through E*Trade and receive communications electronically, you should have received an email on or close to June 14th, from E*Trade with a “from” address of id@ProxyVote.com with the subject heading “Vote now! JAZZ PHARMACEUTICALS PLC Annual Meeting” with instructions about how to vote your shares (please check your “spam” or ‘junk” folder if you did not receive it). If you do not receive communications from E*Trade electronically, you should have received instructions about how to vote your shares in the mail.


image1a.jpg



From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Jazz Pharmaceuticals PLC (JAZZ)

Reference

Frequently asked questions

When did Jazz Pharmaceuticals PLC file this DEFA14A?
Jazz Pharmaceuticals PLC (JAZZ) filed this Additional Proxy Materials (DEFA14A) with the SEC on July 14, 2026. The accession number assigned by EDGAR is 0001628280-26-048166.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Jazz Pharmaceuticals urges shareholders to vote FOR all director nominees and FOR five proposals at the 2026 AGM. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Jazz Pharmaceuticals PLC's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Jazz Pharmaceuticals PLC has filed under CIK 1232524, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer